Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vicarious Surgical Inc. filings document the company's robotic surgery business, capital structure, governance actions, and public-market status. Recent 8-K reports cover operating results, financial condition, executive employment agreement amendments, and NYSE delisting proceedings for the company's Class A common stock, which is quoted on the OTC market under RBOT.
Proxy and shareholder-vote filings describe amendments to the certificate of incorporation related to a reverse stock split authorization and the voting mechanics of the company's Class A and Class B common stock. Form 25 and related reports document removal of the Class A common stock from NYSE listing and registration under Section 12(b).
Khalifa Sammy, identified as a director, a 10% owner and Chief Technology Officer of Vicarious Surgical Inc. (RBOT), reported an equity award on 06/27/2025. The filing shows acquisition of 25,025 stock options with an exercise price of $7.61. The options vest in 48 equal monthly installments beginning on the one-month anniversary of the grant, tying vesting to continued service. The options appear to carry a term that ends on 06/26/2035, and the number of derivative securities beneficially owned following the transaction is 25,025. The form is signed by an attorney-in-fact on 08/11/2025.
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.
Clark Randolph, identified as a director of Vicarious Surgical Inc. (RBOT), reported an acquisition on Form 4 dated 06/27/2025. The filing shows an acquisition of 8,003 stock options with an exercise (conversion) price of $7.61. The options are exercisable into 8,003 shares of Class A common stock and are reported as direct ownership following the transaction.
The filing states all shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service, and lists an associated date of 06/26/2035 in the exercisable/expiration field. The form was signed by an attorney-in-fact on 08/11/2025.
Adam David Sachs, who serves as President and a director of Vicarious Surgical Inc. (RBOT) and is listed as a 10% owner, acquired a grant of stock options on 06/27/2025. The grant covers 38,675 options with an exercise (conversion) price of $7.61 and an expiration date shown as 06/26/2035. The filing reports the options are held directly by the reporting person following the acquisition.
The award vests in 48 equal monthly installments beginning one month after the grant date, subject to continued service through each vesting date. The Form 4 was signed and dated 08/11/2025 by an attorney-in-fact for the reporting person.
Vicarious Surgical director Beverly A. Huss was reported as receiving a stock option to purchase 5,335 shares of Class A common stock with an exercise price of $7.61. The award is a stock option (right to buy) that will vest on June 27, 2026, or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to continued service. The option shows an expiration date in mid-2035 and the post-transaction beneficial position is 5,335 options held directly.
Vicarious Surgical director David D. Ho reported the grant of a stock option covering 5,335 shares of Class A common stock in a Form 4 filed for the issuer Vicarious Surgical Inc. (RBOT). The option has an exercise/conversion price of $7.61, a transaction date of 06/27/2025, and an expiration date of 06/26/2035. The filing shows the reporting person holds 5,335 shares underlying the option following the reported transaction, held in a direct ownership form.
The grant was reported by an attorney-in-fact, signed on 08/11/2025. Per the explanatory note, the option shares will vest on June 27, 2026 (or one day before the next annual meeting), subject to continued service. No earnings or other company financial data are included in this Form 4.
Reporting person listed as FROM STEPHEN, identified as Chief Executive Officer and a director, was granted 297,600 stock options on 08/07/2025 with an $8.92 exercise price. The award vests 25% on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service. The options convert into Class A common stock, are reported as a direct holding, and show an apparent expiration date of 08/06/2035. The grant ties executive pay to share performance and creates potential dilution if the options are exercised.
Ahmad Fuad, identified as a Director of Vicarious Surgical Inc. (RBOT), filed an initial Section 16 Form 3 reporting that he does not beneficially own any securities of the issuer. The filing lists the reporting relationship and confirms no non-derivative or derivative holdings attributed to him.
Vicarious Surgical Inc. (RBOT) Form 3: This initial Section 16 filing reports that the reporting person, identified as "FROM STEPHEN" and listed as both Chief Executive Officer and a Director of Vicarious Surgical Inc., filed an initial statement for an event dated 08/07/2025. The filing explicitly states no securities are beneficially owned by the reporting person. The form is signed by an attorney-in-fact, Erin Checka, on 08/11/2025, and references Exhibit 24.1 (Power of Attorney).